TY - JOUR
T1 - Efficacy of adderall® for attention-deficit/hyperactivity disorder
T2 - A meta-analysis
AU - Faraone, S. V.
AU - Biederman, J.
PY - 2002/9
Y1 - 2002/9
N2 - Stimulant medication has, for many years, been the pharmacological treatment of choice for children and adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Several studies have shown Adderall®, to be efficacious for measures of inattention, hyperactivity-impulsivity, aggression, disruptive behavior, and academic productivity. Although these studies provide useful information for clinicians treating ADHD children and adults, the variability in efficacy among the different types of measures used within each study has not been comprehensively examined. Thus, to provide a clearer picture of what conclusions can be drawn from these studies, we performed a meta-analysis. Data from the six available studies of standard release Adderall® show it to be efficacious for symptoms of inattention, hyperactivity-impulsivity, and aggression, as well as global ratings. Its efficacy was significant for clinician, parent, and teacher ratings, and for both fixed- and best-dose designs.
AB - Stimulant medication has, for many years, been the pharmacological treatment of choice for children and adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Several studies have shown Adderall®, to be efficacious for measures of inattention, hyperactivity-impulsivity, aggression, disruptive behavior, and academic productivity. Although these studies provide useful information for clinicians treating ADHD children and adults, the variability in efficacy among the different types of measures used within each study has not been comprehensively examined. Thus, to provide a clearer picture of what conclusions can be drawn from these studies, we performed a meta-analysis. Data from the six available studies of standard release Adderall® show it to be efficacious for symptoms of inattention, hyperactivity-impulsivity, and aggression, as well as global ratings. Its efficacy was significant for clinician, parent, and teacher ratings, and for both fixed- and best-dose designs.
UR - http://www.scopus.com/inward/record.url?scp=0036727432&partnerID=8YFLogxK
U2 - 10.1177/108705470200600203
DO - 10.1177/108705470200600203
M3 - Article
C2 - 12142863
AN - SCOPUS:0036727432
SN - 1087-0547
VL - 6
SP - 69
EP - 75
JO - Journal of Attention Disorders
JF - Journal of Attention Disorders
IS - 2
ER -